IMC Expects Accelerated Growth in Germany By rescheduling medical cannabis, from a narcotic to a regular prescription, the German medical cannabis market is expected to deliver strong growth, providing IMC Germany with a unique opportunity to further accelerate growth in 2024 after delivering 180% growth in 2023
TORONTO and GLIL YAM, Israel, March 25, 2024 /CNW/ -- IM Cannabis Corp. (CSE: IMCC) (NASDAQ: IMCC) (the "Company", "IMCannabis", or "IMC"), a leading medical cannabis company with operations in Israel and Germany, is welcoming the German government's final approval legalizing cannabis last Friday, as well as the landmark medical cannabis act that has the potential to facilitate access for many new patients as of April 1st.
IMC Expects Accelerated Growth in Germany from the Country's Groundbreaking Cannabis Legalization (newswire.ca)